- Home
- MNMD vs ABL Comparison
MNMD vs ABL Comparison
Compare MNMD & ABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- ABL
- Stock Information
- Founded
- MNMD 2019
- ABL 2004
- Country
- MNMD United States
- ABL United States
- Employees
- MNMD N/A
- ABL N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- ABL Investment Managers
- Sector
- MNMD Health Care
- ABL Finance
- Exchange
- MNMD Nasdaq
- ABL Nasdaq
- Market Cap
- MNMD 509.2M
- ABL 521.6M
- IPO Year
- MNMD N/A
- ABL N/A
- Fundamental
- Price
- MNMD $9.76
- ABL $5.25
- Analyst Decision
- MNMD Strong Buy
- ABL Strong Buy
- Analyst Count
- MNMD 6
- ABL 4
- Target Price
- MNMD $24.67
- ABL $13.13
- AVG Volume (30 Days)
- MNMD 1.3M
- ABL 808.3K
- Earning Date
- MNMD 07-31-2025
- ABL 08-07-2025
- Dividend Yield
- MNMD N/A
- ABL N/A
- EPS Growth
- MNMD N/A
- ABL N/A
- EPS
- MNMD N/A
- ABL N/A
- Revenue
- MNMD N/A
- ABL $134,575,948.00
- Revenue This Year
- MNMD N/A
- ABL $68.84
- Revenue Next Year
- MNMD N/A
- ABL $26.84
- P/E Ratio
- MNMD N/A
- ABL N/A
- Revenue Growth
- MNMD N/A
- ABL 73.39
- 52 Week Low
- MNMD $4.70
- ABL $4.60
- 52 Week High
- MNMD $10.44
- ABL $11.86
- Technical
- Relative Strength Index (RSI)
- MNMD 71.46
- ABL 44.04
- Support Level
- MNMD $9.54
- ABL $4.96
- Resistance Level
- MNMD $10.09
- ABL $5.49
- Average True Range (ATR)
- MNMD 0.47
- ABL 0.20
- MACD
- MNMD 0.18
- ABL 0.11
- Stochastic Oscillator
- MNMD 83.89
- ABL 62.07
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.